Edition:
United Kingdom

Arcturus Therapeutics Ltd (ARCT.OQ)

ARCT.OQ on NASDAQ Stock Exchange Global Market

10.95USD
21 Aug 2019
Change (% chg)

$0.38 (+3.60%)
Prev Close
$10.57
Open
$10.65
Day's High
$10.95
Day's Low
$10.60
Volume
1,846
Avg. Vol
18,524
52-wk High
$15.49
52-wk Low
$4.11

Latest Key Developments (Source: Significant Developments)

Arcturus Therapeutics Q2 Loss Per Share $0.07
Thursday, 15 Aug 2019 

Aug 15 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE.Q2 LOSS PER SHARE $0.07.Q2 EARNINGS PER SHARE ESTIMATE $-0.64 -- REFINITIV IBES DATA.AT JUNE 30, 2019, CO HAD CASH AND CASH EQUIVALENTS TOTALING $55.8 MILLION.  Full Article

Arcturus Therapeutics Announces Additional Registered Direct Offering Of Common Stock
Friday, 2 Aug 2019 

Aug 2 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS ANNOUNCES $2.3 MILLION ADDITIONAL REGISTERED DIRECT OFFERING OF COMMON STOCK.AGREEMENT WITH INSTITUTIONAL INVESTOR FOR PURCHASE & SALE IN OFFERING OF 200,000 SHARES OF COMMON STOCK AT $11.50 PER SHARE.INTENDS TO USE PROCEEDS FROM OFFERING TO FUND CONTINUED RESEARCH AND DEVELOPMENT INITIATIVES IN CONNECTION WITH ITS PRODUCT PIPELINE.  Full Article

Arcturus Therapeutics Says Co & Curevac Terminated Co-Development And Co-Commercialization Agreement Dated Jan 1, 2018
Monday, 29 Jul 2019 

July 29 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS LTD - ON JULY 26, CO & CUREVAC TERMINATED CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT DATED JAN 1, 2018.ARCTURUS THERAPEUTICS LTD - CUREVAC AGREED TO MAKE A ONE-TIME PAYMENT TO CO OF $4 MILLION IN CONSIDERATION FOR TERMINATION.ARCTURUS THERAPEUTICS SAYS AMENDED DEVELOPMENT AND OPTION AGREEMENT WITH CUREVAC AG - SEC FILING.ARCTURUS THERAPEUTICS LTD - AMENDMENT REDUCES OVERALL NUMBER OF MAXIMUM TARGETS TO BE RESERVED AND LICENSED FROM 15 TO 10 TARGETS.ARCTURUS THERAPEUTICS LTD - AMENDMENT MODIFIES TIME PERIOD DURING WHICH CUREVAC MAY SELECT POTENTIAL TARGETS TO BE LICENSED FROM CO.  Full Article

Arcturus Therapeutics Receives Orphan Drug Designation From The U.S. FDA For Arct-810, For Treatment Of Ornithine Transcarbamylase (Otc) Deficiency
Thursday, 27 Jun 2019 

June 27 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION FROM THE U.S. FDA FOR ARCT-810, FOR TREATMENT OF ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY.  Full Article

Arcturus Therapeutics Holdings Files For Mixed Shelf Of Up To $100 Million – SEC Filing
Friday, 21 Jun 2019 

June 21 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS HOLDINGS INC FILES FOR MIXED SHELF OF UP TO $100 MILLION – SEC FILING.  Full Article

Ultragenyx And Arcturus Expand Existing Research License Agreement To Develop Additional Nucleic Acid Therapies For Rare Diseases
Wednesday, 19 Jun 2019 

June 19 (Reuters) - Arcturus Therapeutics Ltd ::ULTRAGENYX AND ARCTURUS THERAPEUTICS EXPAND EXISTING RESEARCH COLLABORATION AND LICENSE AGREEMENT TO DEVELOP ADDITIONAL NUCLEIC ACID THERAPIES FOR RARE DISEASES.ULTRAGENYX PHARMACEUTICAL INC - 30 MILLION OF UPFRONT PAYMENTS TO ARCTURUS, INCLUDING $6 MILLION CASH FOR COLLABORATION AGREEMENT AMENDMENT.ULTRAGENYX PHARMACEUTICAL INC - $30 MILLION OF UPFRONT PAYMENTS TO ARCTURUS, INCLUDING $24 MILLION EQUITY INVESTMENT AT $10 PER SHARE.ULTRAGENYX PHARMACEUTICAL INC - ULTRAGENYX BECOMES ARCTURUS' LARGEST SHAREHOLDER.ULTRAGENYX PHARMACEUTICAL - ARCTURUS IS ENTITLED TO PRECLINICAL, CLINICAL, REGULATORY, AND SALES MILESTONE PAYMENTS FOR PRODUCT DEVELOPED UNDER COLLABORATION.ULTRAGENYX PHARMACEUTICAL INC - KARAH PA KARAH PARSCHAUER, J.D., GENERAL COUNSEL OF CO, JOINING ARCTURUS' BOARD.ULTRAGENYX PHARMACEUTICAL - CERTAIN EARLY-STAGE MILESTONE PAYMENTS ARE REDUCED UNDER AMENDED LICENSE AGREEMENT.ULTRAGENYX PHARMACEUTICAL INC - CEO OF CO JOINING AS ARCTURUS BOARD OBSERVER.ULTRAGENYX PHARMACEUTICAL INC - UNDER AMENDED LICENSE AGREEMENT, TOTAL POTENTIAL MILESTONE PAYMENTS ARE INCREASED DUE TO EXPANDED NUMBER OF TARGETS..ULTRAGENYX PHARMACEUTICAL INC - ARCTURUS IS ALSO ENTITLED TO REIMBURSEMENT OF RELATED RESEARCH EXPENSES AND ROYALTIES ON COMMERCIAL SALES..ULTRAGENYX PHARMACEUTICAL - COS EXPANDED COLLABORATION TO DISCOVER & DEVELOP MRNA, DNA & SIRNA THERAPEUTICS FOR UP TO 12 RARE DISEASE TARGETS.  Full Article

Arcturus Therapeutics Q4 Loss Per Share $0.10
Monday, 18 Mar 2019 

March 18 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND YEAR END 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.10.Q4 EARNINGS PER SHARE ESTIMATE $-0.49 -- REFINITIV IBES DATA.APPOINTED ANDREW SASSINE AS CHIEF FINANCIAL OFFICER.FOR Q4 OF 2018, REPORTED REVENUE OF $7.6 MILLION, COMPARED WITH $2.0 MILLION DURING Q4 OF 2017.CASH, CASH EQUIVALENTS, AND INVESTMENTS TOTALED $36.7 MILLION AS OF DECEMBER 31, 2018.ARCTURUS THERAPEUTICS - BASED ON CURRENT PROJECTIONS, CO'S CURRENT CASH POSITION IS EXPECTED TO BE SUFFICIENT TO SUPPORT OPERATIONS THROUGH EARLY Q1 OF 2020.  Full Article

Arcturus Therapeutics Appoints Andrew Sassine As Chief Financial Officer
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS APPOINTS ANDREW SASSINE AS CHIEF FINANCIAL OFFICER.ARCTURUS THERAPEUTICS LTD - SASSINE HAS BEEN SERVING AS ARCTURUS' INTERIM CHIEF FINANCIAL OFFICER SINCE AUGUST 2018.  Full Article

Arcturus Therapeutics Appoints Four New Directors And Reaches Settlement Agreement With Founder Joseph E. Payne
Tuesday, 29 May 2018 

May 29 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS APPOINTS FOUR NEW DIRECTORS AND REACHES SETTLEMENT AGREEMENT WITH FOUNDER JOSEPH E. PAYNE.ARCTURUS THERAPEUTICS LTD - OTHER KEY TERMS OF SETTLEMENT AGREEMENT INCLUDE MUTUAL RELEASES OF ALL PARTIES.ARCTURUS THERAPEUTICS - OTHER KEY TERMS OF SETTLEMENT AGREEMENT INCLUDE AGREEMENT BY CO AND JOSEPH E. PAYNE TO TERMINATE ALL PENDING LITIGATION.ARCTURUS THERAPEUTICS - SETTLEMENT APPROVED ON MAY 28, 2018 BY ISRAELI DISTRICT COURT.  Full Article

Arcturus Therapeutics issues statement on extraordinary general meeting of shareholders
Tuesday, 27 Feb 2018 

Feb 26 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS - ‍CO SOUGHT TO APPOINT NEW INDEPENDENT AUDITOR IN ORDER TO REPORT FINANCIAL RESULTS, INCLUDING ITS FINANCIAL STATEMENTS FOR 2017​.ARCTURUS-‍IF APPOINTMENT OF AUDITORS FOR 2017 FINANCIAL STATEMENTS IS NOT APPROVED BY SHAREHOLDERS, LIKELIHOOD THAT REPORT WILL NOT BE FILED IN TIMELY MANNER.  Full Article